

Vijay Ramakrishnan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8866416/publications.pdf>

Version: 2024-02-01

11
papers

323
citations

1039880

9
h-index

1281743

11
g-index

11
all docs

11
docs citations

11
times ranked

637
citing authors

#	ARTICLE	IF	CITATIONS
1	TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. <i>American Journal of Hematology</i> , 2010, 85, 675-686.	2.0	56
2	Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway. <i>PLoS ONE</i> , 2012, 7, e50005.	1.1	55
3	PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise. <i>Leukemia and Lymphoma</i> , 2018, 59, 2524-2534.	0.6	54
4	Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies. <i>JCI Insight</i> , 2018, 3, .	2.3	39
5	Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. <i>Clinical Pharmacology: Advances and Applications</i> , 2016, 8, 35.	0.8	30
6	Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. <i>American Journal of Hematology</i> , 2012, 87, 277-283.	2.0	26
7	Signaling Pathways and Emerging Therapies in Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 156-164.	1.2	20
8	Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma. <i>Oncotarget</i> , 2016, 7, 56253-56265.	0.8	18
9	Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001. <i>Leukemia Research</i> , 2014, 38, 1358-1366.	0.4	13
10	In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 78.	2.8	9
11	Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma. <i>Oncotarget</i> , 2018, 9, 34582-34594.	0.8	3